Physician profile
Pamela R Kushner
NPI 1871670828
$1,192,574.13
in general payments reported to CMS, 2019-2025
33 companies · $262K in 2025
The $262K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195K · 2020: $76K · 2021: $89K · 2022: $196K · 2023: $147K · 2024: $228K · 2025: $262K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $378K · Travel and Lodging: $146K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Food and Beverage: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $377,896.87 |
| Travel and Lodging | $146,384.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,988.07 |
| Food and Beverage | $16,372.31 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,075.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $137,764.80 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $128,145.81 | 2019-2025 | Ozempic, Rybelsus, Victoza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121,010.84 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $105,859.59 | 2019-2025 | |
| Boehringer Ingelheim International Gmbh | $94,290.66 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $90,376.39 | 2019-2025 | Farxiga |
| Abbott Laboratories | $89,991.76 | 2019-2025 | Freestyle Libre 3, Freestyle Libre, Afinion 2 |
| Bayer Healthcare Pharmaceuticals INC. | $84,234.31 | 2019-2025 | |
| Astrazeneca Uk Limited | $71,827.42 | 2019-2025 | Farxiga |
| Novo Nordisk As | $68,229.11 | 2019-2025 | |
| Eli Lilly and Company | $66,089.09 | 2020-2025 | Mounjaro, Jardiance |
| Corcept Therapeutics | $28,277.14 | 2021-2025 | Korlym |
| Lilly USA, LLC | $27,748.63 | 2019-2024 | Jardiance |
| Regeneron Pharmaceuticals, INC. | $13,963.61 | 2024 | |
| Currax Pharmaceuticals LLC | $11,468.12 | 2024-2025 | Contrave |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $9,556.69 | 2023-2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $8,421.08 | 2022-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $6,125.00 | 2022-2024 | Xifaxan |
| Azurity Pharmaceuticals, INC. | $4,796.05 | 2025 | Widaplik |
| Astellas Pharma US INC | $4,585.51 | 2023 | Veozah |
| Amgen INC. | $4,228.15 | 2024 | Krystexxa |
| Shield Therapeutics INC | $3,150.00 | 2022 | |
| Biogen, INC. | $3,132.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $2,874.45 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $2,217.98 | 2022 | |
| Orapharma, A Division of Bausch Health US, LLC | $1,312.50 | 2025 | Arestin |
| Intuity Medical INC | $1,260.00 | 2022 | |
| Tonix Medicines, INC. | $828.20 | 2025 | |
| Esperion Therapeutics, INC. | $357.43 | 2023-2025 | Nexletol |
| Insmed, INC. | $200.00 | 2021 | |
| Heartflow, INC. | $103.31 | 2025 | |
| Novartis Pharmaceuticals Corporation | $93.70 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $54.80 | 2019-2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Kushner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.